4h-pyrido[1,2-a]pyrimidin-4-one compounds

Abstract

The present invention relates to compounds of the formula I or II: (I) (II) processes for their preparation and their use as pharmaceutical agents or compositions in the treatment, of neurological disorders.

What is claimed is: 
     
         1 . A compound of formula Ic: 
       
         
           
           
               
               
           
         
         in which 
         R 2  is (CH 2 ) n NR 9 R 10 , 
         R 5  is H or C 1-4  alkyl; 
         R 6  is H or halo; provided that one of R 5  and R 6  is not hydrogen; 
         R 8  is H, C 1-4  alkyl or (CH 2 ) n  aryl; and 
         R 9  and R 10  together with the nitrogen atom to which they are attached form a 5 or 6 membered heterocyclyl in which the heterocyclyl group is optionally substituted with a C 1-4  alkyl aryl group in which the aryl group may be optionally substituted with one or two substituents selected from C 1-6 alkyl, halo, CF 3 , hydroxy, C 1-6  alkoxy or OCF 3 ; 
         n is 0, 1, 2 or 3; 
         each 5 or 6 membered heterocyclyl group may have 1, 2, 3 or 4 heteroatoms selected from O, S and N and may be saturated, unsaturated or aromatic; 
         or a pharmaceutically acceptable salt, stereoisomer or geometric isomer thereof. 
       
     
     
         2 . A compound according to  claim 1  which is a compound of formula Ic wherein R 2  is (CH 2 ) n NR 9 R 10 ; R 5  is H or C 1-4 alkyl; and R 6  is halo. 
     
     
         3 . A compound according to  claim 1  wherein R 5  is hydrogen and R 6  is chloro. 
     
     
         4 . A compound according to  claim 1  wherein R 9  and R 10  form a piperidine ring. 
     
     
         5 . A compound according to  claim 4  wherein the piperidine ring is substituted with CH 2 phenyl in which the phenyl group is optionally substituted with one or two substituents selected from C 1-6 alkyl, halo, CF 3 , hydroxy, C 1-6  alkoxy or OCF 3 . 
     
     
         6 . A compound of according to  claim 1  which is 
       
         
           
           
               
               
           
         
       
     
     
         7 . A compound of formula II 
       
         
           
           
               
               
           
         
         in which 
         R 2  is (CH 2 ) n NR 9 R 10 , 
         R 5  is H or C 1-4  alkyl; 
         R 6  is H or halo; provided that one of R 5  and R 6  is not hydrogen; 
         R 8  is H, C 1-4  alkyl or (CH 2 ) n  aryl; and 
         R 9  and R 10  together with the nitrogen atom to which they are attached form a 5 or 6 membered heterocyclyl in which the heterocyclyl group is optionally substituted with a C 1-4  alkyl aryl group in which the aryl group may be optionally substituted with one or two substituents selected from C 1-6 alkyl, halo, CF 3 , hydroxy, C 1-6  alkoxy or OCF 3 ; 
         n is 0, 1, 2 or 3; 
         each 5 or 6 membered heterocyclyl group may have 1, 2, 3 or 4 heteroatoms selected from O, S and N and may be saturated, unsaturated or aromatic; 
         or a pharmaceutically acceptable salt, stereoisomer or geometric isomer thereof; 
         and 
         M is transition metal. 
       
     
     
         8 . A pharmaceutical agent comprising an effective amount of the compound according to  claim 1 , or a pharmaceutically acceptable salt or stereoisomer or geometric isomer thereof and a pharmaceutically acceptable carrier. 
     
     
         9 . A pharmaceutical agent comprising an effective amount of the compound according to  claim 6 , or a pharmaceutically acceptable salt or stereoisomer or geometric isomer thereof and a pharmaceutically acceptable carrier. 
     
     
         10 . A pharmaceutical agent comprising an effective amount of the compound according to  claim 7 , or a pharmaceutically acceptable salt or stereoisomer or geometric isomer thereof and a pharmaceutically acceptable carrier.